Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products, and specialty services to the life sciences, nutraceuticals, cosmeceuticals and other industries, is making changes to its license offerings. The company announced a strategic decision to offer up to five exclusive licenses to its patented and powerful UltraShear Technology(TM) (UltraShear or UST) platform for the processing of oil-soluble THC concentrates in water into long-term stable, effectively water-soluble and highly bioavailable nanoemulsions. According to the announcement, PBI is offering a limited number of three-year, exclusive, statewide licenses to its patented UltraShear technology platform with processing equipment being custom manufactured for each licensee. The company noted that each exclusive license will be for a single state, with the licensee paying an up-front license fee plus the cost to build the custom equipment, which will be placed in their facility; that equipment will be offered with a no-cost, three-year lease. Licensees will have first rights to negotiate an extension of the license once the initial lease period is over. “The unsatisfactory long onset and full dosing delay associated with THC edibles, contrasted with the health concerns associated with smoking/vaping, continues to present a frustrating dilemma for users,” said Pressure BioSciences director of sales and marketing John Hollister in the press release. “PBIO Issues associated with effectively mixing THC with beverages have remained frustratingly unresolved to date. Over the past few months, we have generated a large amount evidence that our UltraShear platform definitively resolves both of these critical limitations — UltraShear is now poised to redefine the entire cannabis industry.”
To view the full press release, visit https://ibn.fm/z9iyZ
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — utilizes alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter bioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork